Search

Search Constraints

You searched for: Author/Creator Terui, Yasuhito

Search Results

1. A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström's macroglobulinemia. Issue 9 (20th July 2020)

2. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma. Issue 7 (4th June 2021)

3. Bearing 19q13 aberration predicts poor prognosis in non‐germinal centre type of CD5+DLBCL. (26th October 2017)

4. CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. (9th November 2020)

5. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. (8th August 2020)

6. Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan. (3rd April 2013)

7. Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Issue 5 (30th March 2016)

8. Long‐term outcomes and central nervous system relapse in extranodal natural killer/T‐cell lymphoma. Issue 4 (2nd March 2022)

9. ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. (28th November 2020)

10. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Issue 5 (19th May 2017)